Top-News
RXI Pharma
Beiträge:
51
Zugriffe: 18.041 / Heute: 5
Zugriffe: 18.041 / Heute: 5
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,66%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +65,19%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +61,75%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +51,74%
Xtrackers MSCI World Communication Services UCITS ETF 1C
Perf. 12M: +48,64%
www.prnewswire.com/news-releases/...e-iib-to-iv-300067738.html
www.boerse-frankfurt.de/de/aktien/...c+dl+0001+ag+US74979C3034
...bisher mein größter Verlust ( noch nicht realisiert) dieses Jahr.
Dann hoff ich mal auf bessere Zeiten...eigentlich bisher keine schlechten Nachrichten, aber die Aktie wird massiv geshortet...das könnte natürlich heute mit dieser Nachricht sauber in die andere Richtung drehen!
Dann hoff ich mal auf bessere Zeiten...eigentlich bisher keine schlechten Nachrichten, aber die Aktie wird massiv geshortet...das könnte natürlich heute mit dieser Nachricht sauber in die andere Richtung drehen!
MARLBOROUGH, Mass., Sept. 28, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that it has been granted a patent from the State Intellectual Property Office of the People's Republic of China (SIPO) for the composition and methods of use for RXI-109 and other connective tissue growth factor (CTGF) targeting self-delivering RNAi compounds (sd-rxRNA®) for the treatment of fibrotic disorders, including skin fibrosis. The patent is scheduled to expire in 2031.
Logo - photos.prnewswire.com/prnh/20130917/NE80755LOGO
RXI-109 and other CTGF-targeting sd-rxRNA® compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.
"We are pleased with the issuance of this core patent which covers RXI-109 in China," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added, "Not only does this patent further strengthen our intellectual property portfolio, it also expands regional out-licensing and partnering opportunities available with our self-delivering platform. This comes at an important time as we accelerate our business development efforts, one of our seven key initiatives for increasing shareholder value."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of disorders such as alopecia areata, warts, non-malignant skin tumors and cutaneous metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA®) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity.
RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial is planned to initiate this year in ophthalmology. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
Logo - photos.prnewswire.com/prnh/20130917/NE80755LOGO
RXI-109 and other CTGF-targeting sd-rxRNA® compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.
"We are pleased with the issuance of this core patent which covers RXI-109 in China," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added, "Not only does this patent further strengthen our intellectual property portfolio, it also expands regional out-licensing and partnering opportunities available with our self-delivering platform. This comes at an important time as we accelerate our business development efforts, one of our seven key initiatives for increasing shareholder value."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of disorders such as alopecia areata, warts, non-malignant skin tumors and cutaneous metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA®) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity.
RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial is planned to initiate this year in ophthalmology. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
www.nasdaq.com/de/symbol/rxii/real-time
ih.advfn.com/stock-market/NASDAQ/...rporation-RXII/stock-price
kein kauf-oder verkaufempfehlung ( ich selbst bin nicht drin )
kein kauf-oder verkaufempfehlung ( ich selbst bin nicht drin )
rein Freitag natürlich schon im minus wie immer. hört sich aber gut an.
noch besser finde ich allerdings die Story von Phase RX kommen von 5 Dollar sind derzeit bei 1,50 Dollar Handelsvolumen 100,000 Stück davon habe ich 5,000 abgestaubt LOL Sehe hier verzehfachung bis verzwanigzfachungs Potential bei 100% Risiko... Sollte hier ein Pharma oder Biotech Gigant einsteigen bzw. die Plattform lizensieren geht es ab:
PhaseRx has developed a therapeutics platform applicable to a host of diseases. Our initial focus is on three urea cycle disorders (UCDs) as first targets as we believe we can achieve life changing impacts within a reasonable timeframe:
•PRX-OTC for Ornithine Transarbamylase Deficiency (OTCD)
•PRX-ASL for ArgininosuccinateLyase Deficiency (ASLD)
•Argininosuccinatesynthetase 1 (ASS1) deficiency
PhaseRx believes its approach helps mitigate the costs and risks associated with biotech drug development, which are often attributable to a poor understanding of the disease biology and the mechanism of action of the drug candidate, as well as the need for large clinical trials and uncertainty about approvable endpoints. We believe our costs and risks will be lower because:
•The biology of our disease programs is well understood: our target diseases are caused by a bad gene inherited from parents that results in a defective or missing enzyme inside the liver cell.
•The mechanism of action of our therapeutics is clear: we are simply replacing the missing enzyme using our intracellular enzyme replacement therapy approach.
•Clinical proof of concept can be obtained in relatively few patients: We believe we can obtain clinical proofs of concept in very few (10-20) patients, and ultimately achieve product registration based on 30-40 patients, as opposed to hundreds or even thousands of patients needed to obtain clinical proof of concept and registration in other diseases, such as cancer, diabetes, etc.
There is an approvable endpoint in lead programs: We believe lowering of blood ammonia is an approvable endpoint for our lead urea cycle disease (UCD) programs, since an ammonia scavenger was approved by FDA in 2013 for the treatment of the UCDs on the basis of lowering blood ammonia. Also, ammonia can be quickly and readily measured by a blood assay.
phaserx.com/pipeline/
noch besser finde ich allerdings die Story von Phase RX kommen von 5 Dollar sind derzeit bei 1,50 Dollar Handelsvolumen 100,000 Stück davon habe ich 5,000 abgestaubt LOL Sehe hier verzehfachung bis verzwanigzfachungs Potential bei 100% Risiko... Sollte hier ein Pharma oder Biotech Gigant einsteigen bzw. die Plattform lizensieren geht es ab:
PhaseRx has developed a therapeutics platform applicable to a host of diseases. Our initial focus is on three urea cycle disorders (UCDs) as first targets as we believe we can achieve life changing impacts within a reasonable timeframe:
•PRX-OTC for Ornithine Transarbamylase Deficiency (OTCD)
•PRX-ASL for ArgininosuccinateLyase Deficiency (ASLD)
•Argininosuccinatesynthetase 1 (ASS1) deficiency
PhaseRx believes its approach helps mitigate the costs and risks associated with biotech drug development, which are often attributable to a poor understanding of the disease biology and the mechanism of action of the drug candidate, as well as the need for large clinical trials and uncertainty about approvable endpoints. We believe our costs and risks will be lower because:
•The biology of our disease programs is well understood: our target diseases are caused by a bad gene inherited from parents that results in a defective or missing enzyme inside the liver cell.
•The mechanism of action of our therapeutics is clear: we are simply replacing the missing enzyme using our intracellular enzyme replacement therapy approach.
•Clinical proof of concept can be obtained in relatively few patients: We believe we can obtain clinical proofs of concept in very few (10-20) patients, and ultimately achieve product registration based on 30-40 patients, as opposed to hundreds or even thousands of patients needed to obtain clinical proof of concept and registration in other diseases, such as cancer, diabetes, etc.
There is an approvable endpoint in lead programs: We believe lowering of blood ammonia is an approvable endpoint for our lead urea cycle disease (UCD) programs, since an ammonia scavenger was approved by FDA in 2013 for the treatment of the UCDs on the basis of lowering blood ammonia. Also, ammonia can be quickly and readily measured by a blood assay.
phaserx.com/pipeline/
Bin durch Opko Heath die ich auch gekauft habe auf diesen Wert aufmerksam geworden. Stellen Diagnostic Geräte her + Schwesterfirma mit Medikamentenerforschung Biotech + Beteiligungen an kleinen Start-UP Biotechs:
RXi Pharmaceuticals Corp (NASDAQ:RXII) investors should be smiling today, after drug maker Opko Health (NASDAQ:OPK) disclosed in a SEC filing a 5.11% passive stake (446,360 shares) in RXII.
Reacting to the disclosure, RXi Pharmaceuticals shares are rising nearly 25% to $0.88 in early trading Friday.
RXi Pharmaceuticals Corp (NASDAQ:RXII) investors should be smiling today, after drug maker Opko Health (NASDAQ:OPK) disclosed in a SEC filing a 5.11% passive stake (446,360 shares) in RXII.
Reacting to the disclosure, RXi Pharmaceuticals shares are rising nearly 25% to $0.88 in early trading Friday.
1 für 10 Re-Split um die 1,-$-Regel der Nasdaq zu erfüllen.
Vollzug schon am 08.01.2018
"MARLBOROUGH, Mass., Jan. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018"
http://www.ariva.de/news/...als-announces-reverse-stock-split-6714477
Kurs gestern nur noch 0,4688$
Am Montag dann bei ca. 4,68$
Vollzug schon am 08.01.2018
"MARLBOROUGH, Mass., Jan. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018"
http://www.ariva.de/news/...als-announces-reverse-stock-split-6714477
Kurs gestern nur noch 0,4688$
Am Montag dann bei ca. 4,68$
Kommt mal wieder etwas Leben rein..
http://www.ariva.de/rxi_pharmaceuticals-aktie/...refsInput=&xyz=1
http://www.ariva.de/rxi_pharmaceuticals-aktie/...refsInput=&xyz=1
hilft hier wohl zusätzlich zum engen Markt.
Geht ja voll ab... Damit die Marktkapi schon bei 10Mio... ;)
schau mal auf den Freitagsclose in Stuttgart vs. Frankfurt.... Vielleicht eine abenteuerliche Geldtaxe? Bezogen auf Frankfurt ist da kein Sprung
Stuttgart u.Frankfurt braucht man nicht anschauen.
Nasdaq Freitag +27% mit Millionenumsatz
http://www.ariva.de/rxi_pharmaceuticals-aktie/chart
Nasdaq Freitag +27% mit Millionenumsatz
http://www.ariva.de/rxi_pharmaceuticals-aktie/chart
außerdem gab es doch den Sprung am Freitag auch in FRA schon
(Verkleinert auf 60%) 
seekingalpha.com/news/3339608-rxi-pharma-adds-rally-31-percent
Ergebnisse in den abzugebenden Indikationen und fehlender Upfront Deals für die Immunonkologie. Mal abwarten ob Medigene die ersten mit einer Anwendung in der Klinik - z.B. Anti-PD1 - sein werden.
Zacks/SCR hatte am 02.März das Coverage gestartet, sehr ausführlich.
Kursziel 20,-$
scr.zacks.com/News/Press-Releases/...Xis-sd-rxRNA/default.aspx
"...The company has recently announced relationships with Medigene, the Center for Cancer Immune Therapy (CCIT), the University of Minnesota and Gustave Roussy which are all pursuing cancer indications. RXi anticipates that with the help of these partnerships it will have a candidate in human trials by mid-year 2019..."
-
Forschungs-Kooperation mit Medigene seit 11.12.2017
www.medigene.de/investoren-medien/...ng-ihrer-therapeutische/
Kursziel 20,-$
scr.zacks.com/News/Press-Releases/...Xis-sd-rxRNA/default.aspx
"...The company has recently announced relationships with Medigene, the Center for Cancer Immune Therapy (CCIT), the University of Minnesota and Gustave Roussy which are all pursuing cancer indications. RXi anticipates that with the help of these partnerships it will have a candidate in human trials by mid-year 2019..."
-
Forschungs-Kooperation mit Medigene seit 11.12.2017
www.medigene.de/investoren-medien/...ng-ihrer-therapeutische/
(Verkleinert auf 39%)
https://www.ariva.de/news/...karolinska-institutet-enter-into-7121825
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors
Mittwoch, 15.08.2018 15:25 von PR Newswire
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors
Mittwoch, 15.08.2018 15:25 von PR Newswire
Börsenschluss
zum Tiefstpreis von $0.70 ct pro Aktie ...
Sowas kommt selbst in den USA wohl schlecht an.
Hier verdienen nur die Banken ...
zu 0,70 Dollar plus Warrants zu demselben Preis mit 7 Jahren Laufzeit und im Umfang mehr als doppelt so hoch wie die aktuelke Marktkapitalisierung, wenn meine Kenntnisse richtig sind. Kannte die Aktie garnicht bis letzte Woche ...
Aber das ist schon übel für den Anleger und vielleicht gut für die AG ... wer da oben eingestiegen ist in der letzten Woche für den gibt es eine Schnellbeerdigung 1. Klasse ... ohne irgendeine Einschätzung des Potentials ...
Aber das ist schon übel für den Anleger und vielleicht gut für die AG ... wer da oben eingestiegen ist in der letzten Woche für den gibt es eine Schnellbeerdigung 1. Klasse ... ohne irgendeine Einschätzung des Potentials ...
15 Mio. $ Offering @ 0,70$/Share
investors.rxipharma.com/news-releases/...ng-15-million-upsized
Der niedrige Sharepreis bei der KE ist natürlich ein ziemlich schlechtes Zeichen..
-
aber mal was anderes;
Es gab in der Vergangenheit mehrmals starke, kurze Anstiege unter sehr hohem Volumen. Mit anschließendem Abverkauf. Könnte mir vorstellen, das das bald mal wieder passiert. Ich werde wohl mal wieder zugreifen. (Hochriskant, meine pers.Meinung). Dann gleich VK-Limit setzen um so einen Schuß nach oben nicht zu verpassen..
-
aber mal was anderes;
Es gab in der Vergangenheit mehrmals starke, kurze Anstiege unter sehr hohem Volumen. Mit anschließendem Abverkauf. Könnte mir vorstellen, das das bald mal wieder passiert. Ich werde wohl mal wieder zugreifen. (Hochriskant, meine pers.Meinung). Dann gleich VK-Limit setzen um so einen Schuß nach oben nicht zu verpassen..
(Verkleinert auf 39%)
könnten sich vielleicht die schleppenden Verkaufsverhandlungen erklären.
Angeblich soll die frühere CSO 2012 Unterlagen gestohlen und dann später 2013 als Professorin an der UMass für eine Patentanmeldung benutzt haben.
Dort hat sie mit Alexey Wolfson einem anderen ex-RXI Mitarbeitern scheinbar auch eine eigene Firma ADViRNA gegründet, die aber auf ihrer Homepage auch mehrfach auf RXI verweist.
RXI verlangt wohl Schadensersatz und eine Rücknahme des Patents sowie die Entlassung der Professorin, da sie als frühere CSO der RXI unter einem unterschriebenen Wettbewerbsverbot steht.
Alles etwas merkwürdig, wo man bis vor kurzen scheinbar noch gut mit allen Partien zusammengearbeitet und gemeinsam wissenschaftliche Artikel veröffentlicht hat.
Alles sehr dubious - meine Meinung - KEINE Handelsempfehlung.
"..The poster, titled "sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer" (Poster #P258),
will be available for viewing from 12:20–1:50 p.m. ET and 7:00–8:30 p.m. ET on Saturday,
November 10, 2018.."
https://www.ariva.de/news/...esent-new-data-demonstrating-the-7243844
will be available for viewing from 12:20–1:50 p.m. ET and 7:00–8:30 p.m. ET on Saturday,
November 10, 2018.."
https://www.ariva.de/news/...esent-new-data-demonstrating-the-7243844
"the name of our company will change from RXi Pharmaceuticals to Phio Pharmaceuticals Corporation"
so kann man im Quartalsbericht nachlesen.
Angesichts der Kurskapriolen wirkt dies nicht besonders vertrauensbildend auf mich. Hier scheint man leichter Neulinge in die Aktie locken zu wollen, für die der Rauswurf aus dem NASDAQ wegen der Penny-stock Kurse bis zum Mai 2019 schon wieder im Raume steht - und dies trotz eines 10:1 Resplit vor einem Jahr und einer Kapitalerhöhung im Oktober mit Riesenverwässerung für nicht einmal 15 Millionen US-Dollar.
so kann man im Quartalsbericht nachlesen.
Angesichts der Kurskapriolen wirkt dies nicht besonders vertrauensbildend auf mich. Hier scheint man leichter Neulinge in die Aktie locken zu wollen, für die der Rauswurf aus dem NASDAQ wegen der Penny-stock Kurse bis zum Mai 2019 schon wieder im Raume steht - und dies trotz eines 10:1 Resplit vor einem Jahr und einer Kapitalerhöhung im Oktober mit Riesenverwässerung für nicht einmal 15 Millionen US-Dollar.
versucht über Auslizensierungen noch vor Rauswurf die Kurve zu kriegen;
seekingalpha.com/article/...results-earnings-call?part=single
"..In addition to our reduction in our spending, we were able to complete the financing that has resulted in an extended cash runway for our company into the second half of 2020. As side effect of this financing, our share price has dropped below the $1 mark that has triggered related from that NASDAQ requesting that we take action to bring the share price back above [one-to-one] mark in the next 6 months. Ms. Kontulis, our Senior Director of Finance will provide more color to these financial developments.
As mentioned in previous calls, we also have active profits underway to sale or out license our dermatology and ophthalmology assets aiming and trading additional non-diluted cash that would further extend our cash flow rate well into 2021. We started this process with the support an advisory firm and have seen good interest on the dermatology side and excellent traction in the ophthalmology space. The actual process has accelerated recently with the final clinical data becoming available.."
Pfeifen im Walde ?!
seekingalpha.com/article/...results-earnings-call?part=single
"..In addition to our reduction in our spending, we were able to complete the financing that has resulted in an extended cash runway for our company into the second half of 2020. As side effect of this financing, our share price has dropped below the $1 mark that has triggered related from that NASDAQ requesting that we take action to bring the share price back above [one-to-one] mark in the next 6 months. Ms. Kontulis, our Senior Director of Finance will provide more color to these financial developments.
As mentioned in previous calls, we also have active profits underway to sale or out license our dermatology and ophthalmology assets aiming and trading additional non-diluted cash that would further extend our cash flow rate well into 2021. We started this process with the support an advisory firm and have seen good interest on the dermatology side and excellent traction in the ophthalmology space. The actual process has accelerated recently with the final clinical data becoming available.."
Pfeifen im Walde ?!
scheint mir die Nennung des Zeithorizonts "well into 2021". Aktuell erwartet man bis in die zweite Hälfte 2020 finanziert zu sein. Damit dürfte der finanzielle Beitrag eines Verkaufs der Altprojekte begrenzt sein und maximal ca. 1 Jahr betragen. Bei einem Barmittelverbrauch von rund 2 Millionen pro Quartal entspricht dies ca. maximal 8-10 Millionen Euro - was ziemlich enttäuschend sein dürfte.
bei weitem nicht - die Inhalte wurden einfach übernommen und die sonstigen Umstände der Merkwürdigkeiten ist damit nur um eine rote Flagge umfangreicher geworden.
Die Hoffnung auf neue Kurse bleibt und wenn es auch erst im nächsten Jahr Februar soweit sein sollte ... (dann sind die Sonderbedingungen des scheidenden CEO mit der Zahlung der Hälfte des Gehaltes in Aktien sowie die zusätzlichen Verpflichtungen gegenüber den ehemaligen MirImmune Eignern bei einem Deal geringer)
Meine Meinung - KEINE Empfehlung.
Die Hoffnung auf neue Kurse bleibt und wenn es auch erst im nächsten Jahr Februar soweit sein sollte ... (dann sind die Sonderbedingungen des scheidenden CEO mit der Zahlung der Hälfte des Gehaltes in Aktien sowie die zusätzlichen Verpflichtungen gegenüber den ehemaligen MirImmune Eignern bei einem Deal geringer)
Meine Meinung - KEINE Empfehlung.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Phio Pharmaceuticals Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 521 | Phio Pharmaceuticals | DA_BUA | RichyBerlin | 16.10.24 20:53 | |
| 50 | RXI Pharma | iwanooze | iTechDachs | 25.04.21 01:19 |
